Saturday 17 October 2026
Export OSUR’s income statement to Excel — free account
OraSure Technologies, Inc.
OSUR Healthcare Medical Instruments & Supplies
OraSure Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $115.0 million, down 38.1% from fiscal 2024. In the quarter to June 2026, revenue fell 1.93%, EPS grew 134.6%, free cash flow fell 1.40% and total debt fell 8.27%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.61
0.20
−5.25%
Follow OSUR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.86 | 1.55 | 1.85 | 2.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(23.27) | (19.77) | (15.04) | (31.02) | |
P/B ratio |
0.65 | 0.52 | 0.67 | 0.97 | |
Price to Tangible BV |
0.77 | 0.64 | 0.83 | 1.20 | |
EV/Sales |
0.14 | (0.19) | 0.29 | 1.31 | |
EV/EBITDA |
0.00 | 0.35 | 0.00 | 0.00 | |
EV/Operating CF |
(0.45) | 0.44 | (0.75) | (3.43) | |
EV/FCF |
(0.42) | 0.40 | (0.66) | (3.02) | |
Quick Ratio |
5.98 | 5.57 | 4.61 | 7.48 | |
Current Ratio |
7.03 | 6.58 | 5.46 | 8.88 | |
Net Debt/EBITDA |
15.87 | 11.25 | 8.45 | (20.54) | |
Debt/Assets |
0.03% | 0.02% | 0.04% | 0.03% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.28 | 0.26 | 0.27 | 0.28 | |
Operating CF/Net income |
0.73 | 0.47 | 0.62 | (1.59) | |
Capex/Depreciation |
(0.33) | (0.75) | (0.39) | (1.02) | |
Research and Development Expense of Revenue |
37.31% | 42.66% | 48.90% | 30.80% | |
Selling, General and Administrative Expense of Revenue |
64.17% | 61.29% | 76.37% | 68.65% | |
Intangible Assets out of Total Assets |
0.14 | 0.15 | 0.16 | 0.17 | |
Share Based Compensation of Revenue |
10.47% | 5.46% | 9.91% | 7.46% | |
Graham Net Nets |
0.95 | 1.12 | 0.84 | 0.59 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(24.92%) | (38.43%) | (34.67%) | (15.47%) | |
Free Cash Flow Yield |
(18.25%) | (29.93%) | (23.28%) | (15.87%) | |
Revenue per Share |
0.37 | 0.36 | 0.40 | 0.44 | |
Operating CF per Share |
(0.14) | (0.12) | (0.20) | (0.14) | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.03) | |
Free Cash Flow per Share |
(0.15) | (0.15) | (0.21) | (0.18) | |
Cash per Share |
2.97 | 2.71 | 2.54 | 2.33 | |
Shareholders Equity per Share |
4.96 | 4.64 | 4.50 | 4.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.96 | 4.64 | 4.50 | 4.61 | |
Free Cash Flow |
(10.89) | (10.81) | (14.81) | (12.33) | |
Working Capital |
242.76 | 222.11 | 196.70 | 197.82 | |
Capital Expenditures |
(0.82) | (1.81) | (0.91) | (2.41) | |
Net Current Asset Value |
221.89 | 199.57 | 174.94 | 180.16 | |
EV/EBIT |
0.00 | 0.30 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.07 | 0.03 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
25.63 | 23.01 | 23.97 | 26.63 | |
Average Payables |
7.97 | 7.35 | 9.22 | 7.39 | |
Average Inventory |
36.14 | 32.63 | 32.99 | 31.72 | |
Average Assets |
443.59 | 441.41 | 418.39 | 402.79 | |
Average Common Equity |
393.77 | 375.58 | 354.80 | 349.25 |
Columns are period end dates